(S)-2-羟基-3-(4-硝基苯基)丙酸 | 33173-27-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 中文名称: (S)-2-羟基-3-(4-硝基苯基)丙酸
• 英文名称: (S)-3-(4-nitrophenyl)-2-hydroxypropionic acid
• 英文别名: L-(-)-3-(4-nitrophenyl)lactic acid；(S)-2-hydroxy-3-(4-nitrophenyl)propionic acid；L-(-)-p-Nitrophenyl-milchsaeure；(S)-2-hydroxy-3-(4-nitrophenyl)propanoic acid；(2S)-2-hydroxy-3-(4-nitrophenyl)propanoic acid
• CAS: 33173-27-2
• 化学式: C₉H₉NO₅
• 分子量: 211.174
• InChiKey: JUHYZGPSJIUDDU-QMMMGPOBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P330,P363,P501
• 危险性描述：
  H302,H312,H332

反应信息

• 作为反应物：
  描述：

  (S)-2-羟基-3-(4-硝基苯基)丙酸 在 Lactobacillus paracasei DSM 20207 作用下， 以 水 为溶剂， 反应 24.0h， 生成 2-hydroxy-3-(4-nitrophenyl)propanoic acid
  参考文献：
  名称：

  乳酸菌对（杂）芳基-脂肪族α-羟基羧酸的生物催化外消旋化。通过氧化-还原序列进行

  摘要：

  一系列（杂）芳基-和（二）芳基-脂肪族α-羟基羧酸的生物催化外消旋化已通过使用乳杆菌属的整个静息细胞实现。基本上温和的（生理）反应条件确保抑制不需要的副反应，例如消除、分解或缩合。使用副干酪乳杆菌 DSM 20207 无细胞提取物的辅因子/抑制剂研究表明，添加氧化还原辅因子 (NAD+/NADH) 导致外消旋化率明显增加，而在存在硫代-NAD+ 的情况下观察到强烈的抑制作用，这表明外消旋化是通过氧化还原序列进行的，而不是“外消旋酶”的参与。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2006)

  DOI：

  10.1002/ejoc.200600454
• 作为产物：
  描述：

  3-(4-硝基苯基)丙酸 在 硫酸 、 sodium nitrite 作用下， 以 水 、 丙酮 为溶剂， 反应 18.0h， 以96%的产率得到(S)-2-羟基-3-(4-硝基苯基)丙酸
  参考文献：
  名称：

  [EN] NOVEL COMPOUNDS AND THEIR USE AS ANTIDIABETIC AND HYPOLIPIDEMIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  [FR] NOUVEAUX COMPOSES ET LEUR UTILISATION EN MEDECINE, LEUR PROCEDE DE PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT

  摘要：

  公开号：

  WO2005040102A3

文献信息

• Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
  申请人：DR. REDDY'S LABORATORIES LIMITED

  公开号：US20030229083A1

  公开（公告）日：2003-12-11

  The present invention relates to novel antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds of formula (I), 1 their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.

  本发明涉及具有化学式（I）的新型抗糖尿病、降血脂、抗肥胖和降胆固醇化合物，其衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂化物以及含有它们的药学上可接受的组合物。
• [EN] BASIC SALTS AND MONOHYDRATES OF CERTAIN ALPHA, BETA-PROPRIONIC ACID DERIVATIVE<br/>[FR] SELS DE BASE ET MONOHYDRATES DE CERTAINS DERIVES D'ACIDE ALPHA, BETA-PROPRIONIQUE
  申请人：REDDYS LAB LTD DR

  公开号：WO2006001795A1

  公开（公告）日：2006-01-05

  The invention provides novel salts of (S)-2-methoxy-3-[4-3-(4-methanesulfonyloxyphenyl)propylamino}phenyl] proprionic acid, including Arginine salt of (S)-2-methoxy-3-[4-3-(4-methanesulfonyloxyphenyl)propilamino}phenyl] proprionic acid monohydrate, Arginine salt of (S)-2-methoxy-3-[4-3-(4-methanesulfonyloxyphenyl)propylamino}phenyl] proprionic acid, and (S)-2-methoxy-3-[4-3-(4-methanesulfonyloxyphenyl)propylamino}phenyl] proprionic acid monohydrate. Various aspects and embodiments are included. Compositions containing novel salts of (S)-2-methoxy-3-[4-3-(4-methanesulfonyloxyphenyl)propylamino}phenyl] proprionic acid are also provided.

  本发明提供了(S)-2-甲氧基-3-[4-3-(4-甲磺酰氧苯基)丙基氨基}苯基]丙酸的新型盐，包括(S)-2-甲氧基-3-[4-3-(4-甲磺酰氧苯基)丙基氨基}苯基]丙酸精氨酸盐单水合物、(S)-2-甲氧基-3-[4-3-(4-甲磺酰氧苯基)丙基氨基}苯基]丙酸精氨酸盐和(S)-2-甲氧基-3-[4-3-(4-甲磺酰氧苯基)丙基氨基}苯基]丙酸单水合物。本发明还包括各种方面和实施例。本发明还提供了含有(S)-2-甲氧基-3-[4-3-(4-甲磺酰氧苯基)丙基氨基}苯基]丙酸新型盐的组合物。
• Basic salts and monohydrates of certain alpha, beta-propionic acid derivative
  申请人：Palle Venkata Raghavendra Charyulu

  公开号：US20050277693A1

  公开（公告）日：2005-12-15

  The invention provides novel salts of (S)-2-methoxy-3-[4-3-(4-methanesulfonyloxyphenyl)propylamino} phenyl] propionic acid, including Arginine salt of (S)-2-methoxy-3-[4-3-(4-methanesulfonyloxyphenyl)propylamino} phenyl] propionic acid monohydrate, Arginine salt of (S)-2-methoxy-3-[4-3-(4-methanesulfonyloxyphenyl) propylamino} phenyl] propionic acid, and (S)-2-methoxy-3-[4-3-(4-methanesulfonyloxyphenyl)propylamino} phenyl] propionic acid monohydrate. Various aspects and embodiments are included. Compositions containing novel salts of (S)-2-methoxy-3-[4-3-(4-methanesulfonyloxyphenyl) propylamino}phenyl] propionic acid are also provided.

  本发明提供了(S)-2-甲氧基-3-[4-3-(4-甲烷磺酰氧苯基)丙基氨基}苯基]丙酸的新型盐，包括(S)-2-甲氧基-3-[4-3-(4-甲烷磺酰氧苯基)丙基氨基}苯基]丙酸单水合物的精氨酸盐，(S)-2-甲氧基-3-[4-3-(4-甲烷磺酰氧苯基)丙基氨基}苯基]丙酸的精氨酸盐，以及(S)-2-甲氧基-3-[4-3-(4-甲烷磺酰氧苯基)丙基氨基}苯基]丙酸单水合物。包括各种方面和实施例。还提供了含有(S)-2-甲氧基-3-[4-3-(4-甲烷磺酰氧苯基)丙基氨基}苯基]丙酸新型盐的组合物。
• Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them
  申请人：Bhuniya Debnath

  公开号：US20050113368A1

  公开（公告）日：2005-05-26

  The present invention relates to novel antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds of formula (I) their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them, to a process for preparing such compounds. More particularly, the present invention relates to novel alkyl carboxylic acids of the general, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them, to a process for preparing such compounds. The present invention also relates to processes for the preparation of the compounds of formula (I), novel intermediates, processes for their preparation, their use in the preparation of the above said compounds and their use as antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds.

  本发明涉及公式（I）的新型抗糖尿病、降脂、抗肥胖和降胆固醇化合物及其衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和包含它们的药学上可接受的组合物，以及制备这些化合物的方法。更具体地说，本发明涉及一般的烷基羧酸及其衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和包含它们的药学上可接受的组合物，以及制备这些化合物的方法。本发明还涉及公式（I）化合物的制备方法、新型中间体的制备方法、以及它们在制备上述化合物和作为抗糖尿病、降脂、抗肥胖和降胆固醇化合物的用途。
• Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them
  申请人：Debnath Bhunia

  公开号：US20070093476A1

  公开（公告）日：2007-04-26

  The present invention relates to novel compounds of formula (I) and their pharmaceutically acceptable salts, wherein ring “Ar 1 ” represents a monocyclic or polycyclic aromatic or partially saturated aromatic polycyclic, which may optionally contain up to 3 heteroatoms selected from N, S or O. The said monocyclic or polycyclic ring may be unsubstituted or have up to 4 substituents which may be identical or different; m and n independently represents an integer from 0 to 6; A represents O, S or bond; Y is selected from (CH 2 ) p′ (CH 2 ) p B(CH 2 ) q′ (CH 2 ) r B(CH 2 ) p D(CH 2 ) p′ where p, q and r each independently represents an integer from 0 to 6; B and D independently represents S, O, NR 4 or a bond, with a proviso that when B and D represents hereto atom p is not zero; R 4 represents hydrogen, alkyl, alkenyl, —S(O) 2 —R 8 or —C(O)R 8 where R 8 is alkyl, alkoxy; R 5 and R 6 independently represents hydrogen, alkyl, cycloalkyl or alkoxy; R 5 and R 6 together may form 3-8 membered cyclic ring which may optionally contains one or two hereto atoms selected from O, S or N; R 7 represents hydrogen, optionally substituted groups selected form alkyl, cycloalkyl, alkenyl or alkynyl. The present invention also relates to a process for preparation of compounds of formula (I), to pharmaceutical compositions containing compounds of formula (I) and their use in particular as antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic agents.

  本发明涉及公式（I）的新化合物及其药学上可接受的盐，其中环“Ar1”表示单环或多环芳香或部分饱和芳香多环，可选含有最多3个选自N、S或O的杂原子。所述的单环或多环环可以未取代或具有最多4个相同或不同的取代基；m和n分别表示0到6的整数；A表示O、S或键；Y选自（CH2）p′（CH2）pB（CH2）q′（CH2）rB（CH2）pD（CH2）p′，其中p、q和r各自独立地表示0到6的整数；B和D分别表示S、O、NR4或键，条件是当B和D表示杂原子时，p不为零；R4表示氢、烷基、烯基、—S（O）2—R8或—C（O）R8，其中R8为烷基、烷氧基；R5和R6各自独立地表示氢、烷基、环烷基或烷氧基；R5和R6可以一起形成3-8成员环，该环可以选择性地包含选自O、S或N的一个或两个杂原子；R7表示氢、可选地从烷基、环烷基、烯基或炔基中选择的取代基。本发明还涉及公式（I）化合物的制备方法，含有公式（I）化合物的制药组合物以及其作为抗糖尿病、降脂、抗肥胖和降胆固醇药物的应用。